Velphoro (sucroferric oxyhydroxide) provides potent phosphorus control

For patients on dialysis:
More phosphorus control,
fewer pills, more flexibility1,2

Velphoro is how.
Greater potency is why.1,3,4

Velphoro (sucroferric oxyhydroxide) provides potent phosphorus control

Give your patients the eff⁠icacy they need
with the most potent phosphate binder3,4

*A retrospective analysis of deidentified pharmacy data from 1,029 adult in-center hemodialysis patients who were switched to Velphoro during routine care between April 2014 and March 2015. The decision to switch phosphate binders (PBs) was made on a clinical basis and the reasons underlying this change were not available. Outcomes included the proportion of patients with phosphorus levels ≤5.5 mg/dL and the mean prescribed PB pills/day at baseline (3 months prior to Velphoro) and during Velphoro follow-up (6 months after switch to Velphoro, n=424).2

References: 1. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2020. 2. Coyne DW, Ficociello LH, Parameswaran V, et al. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin Nephrol. 2017;88(2):59-67. 3. Wilhelm M, Gaillard S, Rakov V, Funk F. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;81(4):251-258. 4. Gutekunst L. An update on phosphate binders: a dietitian’s perspective. J Ren Nutr. 2016;26(4):209-218. 5. Data on file. Fresenius Medical Care North America. Waltham, MA.